Lisata added an independent director with finance and biopharma experience to its audit committee, which could strengthen oversight. The filing reports no change to its business or results, so the benefit is limited.
Farrow's finance and biopharma experience could help the board review Lisata's finances and company decisions. The filing reports no change to the company's business results, so the benefit is limited to oversight.
Follow Lisata Therapeutics, Inc. (LSTA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LSTA